TESSA THERAPEUTICS' 'OFF-THE-SHELF' THERAPY YIELDS PROMISING RESULTS IN EARLY-STAGE STUDY OF HODGKIN LYMPHOMA

KUALA LUMPUR, June 16 (Bernama) -- Tessa Therapeutics Ltd (Tessa), a clinical-stage cell therapy company announced promising safety and efficacy data from a study of its off-the-shelf CD30.CAR EBVST therapy (TT11X) in patients with relapsed or refractory (R/R) Hodgkin lymphoma.

The results were presented by Tessa collaborators at the Baylor College of Medicine in an oral podium presentation at the 17th International Conference on Malignant Lymphoma (ICML) taking place at Lugano, Switzerland.

According to Tessa in a statement, TT11X, its allogeneic “off-the-shelf” cell therapy, is based on the company’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.

Tessa Chief Medical Officer and Chief Scientific Officer, Ivan Horak said: “The data presented at ICML are very promising and further validate our “off-the-shelf” CD30.CAR EBVST allogeneic cell therapy platform in R/R Hodgkin lymphoma.

“Tessa is steadfastly focused on advancing the development of TT11X as a potential treatment for CD30-positive lymphomas, while targeting opportunities to extend the EBVST platform to other cancer indications and enhance the cell performance and durability of the technology.”

The podium presentation titled, “Off-the-shelf CD30.CAR EBV-specific T cells provide a safe and effective therapy for HL”, reported data from 18 heavily pre-treated patients with R/R Hodgkin lymphoma who were administered TT11X across four dosing levels.

An overall response rate of 78 per cent (14/18 patients) was observed across all four dose levels, including seven complete responses and seven partial responses, with higher doses producing improved clinical responses.

Additionally, TT11X was demonstrated to be well tolerated with no dose-limiting toxicities observed, including no evidence of graft-versus-host disease (GVHD) or immune effector cell-associated neurotoxicity syndrome (ICANS).

Tessa is currently advancing a pipeline of products that utilise CD30.CAR-modified EBVSTs, including its lead allogeneic cell therapy, TT11X, which is being co-developed with the Baylor College of Medicine for the treatment of relapsed or refractory CD30-positive lymphomas.

-- BERNAMA